News in the Life Sciences Industry

The Australian Government invests $40 million to provide patients affordable access to two new medicine listings through the Pharmaceutical Benefit Scheme (PBS)

STOCKHOLM, Aug. 23, 2019 /PRNewswire/ -- Cantargia AB today announce new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The molecular target for CAN04, IL1RAP, has been detected on the cancer cells in approximately 80 % of... Read more ››

CORK, Ireland, Aug. 22, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen of its rilpivirine and ViiV Healthcare's... Read more ››

STOCKHOLM, Aug. 22, 2019 /PRNewswire/ --

LUND, Sweden, Aug. 22, 2019 /PRNewswire/ -- "We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered clinical trials in solid cancer," Martin Welschof, CEO BioInvent

LUND, Sweden, Aug. 22, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page Read more ››

STOCKHOLM, Aug. 22, 2019 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the January - June 2019 is now available on the company's website: Read more ››

LINKÖPING, Sweden, Aug. 22, 2019 /PRNewswire/ -- Linköping, Sweden - August 22, 2019 - The international medical imaging IT and cybersecurity company Read more ››

LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences:

LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, today announced that the earlier communicated phase l/lla clinical trial in... Read more ››

STOCKHOLM, Aug. 21, 2019 /PRNewswire/ --

LUND, Sweden, Aug. 20, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019, for investors, analysts and media.

LUND, Sweden, Aug. 20, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. ("Biotheus"), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license agreement, Alligator... Read more ››